These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 3457980)

  • 41. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
    Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
    Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potentiation of antitumor activity of vincristine by the biscoclaurine alkaloid cepharanthine.
    Kato T; Suzumura Y
    J Natl Cancer Inst; 1987 Sep; 79(3):527-32. PubMed ID: 3476792
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-antitumor vinca alkaloids reverse multidrug resistance in P388 leukemia cells in vitro.
    Inaba M; Nagashima K
    Jpn J Cancer Res; 1986 Feb; 77(2):197-204. PubMed ID: 3082832
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement.
    Naito M; Tsuruo T
    Cancer Res; 1989 Mar; 49(6):1452-5. PubMed ID: 2924298
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhancement of doxorubicin and vinblastine sensitivity in anthracycline-resistant P388 cells.
    Ramu A; Shan TC; Glaubiger D
    Cancer Treat Rep; 1983 Oct; 67(10):895-9. PubMed ID: 6354437
    [TBL] [Abstract][Full Text] [Related]  

  • 46. R-dl-verapamil downmodulates multidrug resistance of KBv200 cells to vincristine and doxorubicin.
    Fang G; Yang YL; Li JS; Zhang ZX
    Zhongguo Yao Li Xue Bao; 1999 Jul; 20(7):647-50. PubMed ID: 10678132
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overcoming of vinblastine resistance by isoquinolinesulfonamide compounds in adriamycin-resistant leukemia cells.
    Wakusawa S; Nakamura S; Tajima K; Miyamoto K; Hagiwara M; Hidaka H
    Mol Pharmacol; 1992 Jun; 41(6):1034-8. PubMed ID: 1614407
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines.
    Dong J; Naito M; Tatsuta T; Seimiya H; Johdo O; Tsuruo T
    Oncol Res; 1995; 7(5):245-52. PubMed ID: 8534930
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073.
    Sato W; Fukazawa N; Suzuki T; Yusa K; Tsuruo T
    Cancer Res; 1991 May; 51(9):2420-4. PubMed ID: 1673087
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of verapamil on daunomycin cellular retention and cytotoxicity in P388 leukemic cells.
    Yanovich S; Preston L
    Cancer Res; 1984 May; 44(5):1743-7. PubMed ID: 6713377
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Taxol resistance and its reversal by synthetic isoprenoids in human bladder cancer cell line.
    Nakagawa M; Enokida H; Gotanda T; Tachiwada T; Imazono Y; Kubo H; Nishiyama K; Suzuki S; Inomata K; Kishiye T
    Aktuelle Urol; 2003 Jul; 34(4):250-2. PubMed ID: 14566676
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reversal of multidrug resistance by an immunosuppressive agent FK-506.
    Naito M; Oh-hara T; Yamazaki A; Danki T; Tsuruo T
    Cancer Chemother Pharmacol; 1992; 29(3):195-200. PubMed ID: 1370765
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sensitivity to anthracyclines in P388/dx leukaemia cells.
    Bossa R; Dasdia T; Galatulas I; Zunino F
    Anticancer Res; 1986; 6(5):1037-9. PubMed ID: 3099628
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modulation of doxorubicin efficacy in P388 leukemia following co-administration of verapamil in mini-osmotic pumps.
    Slate DL; Fraser-Smith EB; Rosete JD; Freitas VR; Kim YN; Casey SM
    In Vivo; 1993; 7(6A):519-23. PubMed ID: 8193270
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potentiation of vincristine by vitamin A against drug-resistant mouse leukaemia cells.
    Nogae I; Kikuchi J; Yamaguchi T; Nakagawa M; Shiraishi N; Kuwano M
    Br J Cancer; 1987 Sep; 56(3):267-72. PubMed ID: 3663474
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic potency of transduction with herpes simplex virus thymidine kinase gene against multidrug resistant mouse leukemia cells.
    Takenaga K; Tagawa M; Sakiyama S
    Anticancer Res; 1996; 16(2):681-5. PubMed ID: 8687114
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synergistic effect in culture of bleomycin-group antibiotics and N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine, a synthetic isoprenoid.
    Tomida A; Suzuki H
    Jpn J Cancer Res; 1990 Nov; 81(11):1184-90. PubMed ID: 1702416
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [In vitro characterization of S9788, a new modulator of multidrug resistance].
    Pérez V; Pierré A; Léonce S; Anstett M; Prost JF; Atassi G
    Bull Cancer; 1993 Apr; 80(4):310-25. PubMed ID: 8173185
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A simple fluorometric method to discriminate adriamycin-resistant subline from adriamycin-sensitive parental P388 murine leukemia cell line.
    Dekker K; Kojima N; Yamamoto S; Tatsumi K; Mino M; Yagi K
    Biochem Int; 1987 Jun; 14(6):997-1001. PubMed ID: 3453100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.